Year archive

Pharming Group N.V. — 2026 filings

All 38 regulatory filings released by Pharming Group N.V. (PHARM) in 2026, sourced directly from the official regulator.

38 Filings

2026 Period

2026 filings (38)

Filing	Released	Lang
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS Regulatory Filings	2026-06-04	Dutch
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS Regulatory Filings	2026-06-04	English
6-K Regulatory Filings	2026-06-04	English
Pharming Group announces results of 2026 Annual General Meeting of Shareholders Declaration of Voting Results & Voting Rights Announcements	2026-05-29	Dutch
Pharming Group announces results of 2026 Annual General Meeting of Shareholders Declaration of Voting Results & Voting Rights Announcements	2026-05-29	English
6-K Regulatory Filings	2026-05-28	English
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union Regulatory Filings	2026-05-25	Dutch
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union Regulatory Filings	2026-05-25	English
6-K Regulatory Filings	2026-05-22	English
6-K - Pharming Group N.V. (0001828316) (Filer) Regulatory Filings	2026-05-07	English
6-K - Pharming Group N.V. (0001828316) (Filer) Earnings Release Q1 2026	2026-05-07	English
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 Interim / Quarterly Report Q1 2026	2026-05-07	English
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 Interim / Quarterly Report Q1 2026	2026-05-07	English
6-K - Pharming Group N.V. (0001828316) (Filer) AGM Information	2026-04-16	English
Pharming Group announces the 2026 Annual General Meeting of Shareholders Regulatory Filings	2026-04-16	Dutch
Pharming Group announces the 2026 Annual General Meeting of Shareholders Proxy Solicitation & Information Statement	2026-04-16	English
20-F/A - Pharming Group N.V. (0001828316) (Filer) Annual Report FY 2025	2026-04-13	English
6-K - Pharming Group N.V. (0001828316) (Filer) Report Publication Announcement	2026-04-02	English
20-F - Pharming Group N.V. (0001828316) (Filer) Annual Report FY 2025	2026-04-02	English
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F Report Publication Announcement	2026-04-02	Dutch
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F Report Publication Announcement	2026-04-02	English
Pharming Group N.V., Jaarlijkse financiële verslaggeving Annual Report FY 2025	2026-04-02	English
6-K - Pharming Group N.V. (0001828316) (Filer) Regulatory Filings	2026-03-27	English
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older Regulatory Filings	2026-03-27	Dutch
Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older Regulatory Filings	2026-03-27	English
6-K - Pharming Group N.V. (0001828316) (Filer) Regulatory Filings	2026-03-24	English
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older Regulatory Filings	2026-03-24	Dutch
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older Regulatory Filings	2026-03-24	English
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Earnings Release Q4 2025	2026-03-12	Dutch
Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow Earnings Release FY 2025	2026-03-12	English
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Earnings Release FY 2026	2026-02-03	Dutch
Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day Earnings Release FY 2026	2026-02-03	English
6-K Filing Investor Presentation	2026-02-03	English
Pharming ontvangt Complete Response Letter van de FDA voor sNDA voor Joenja (leniolisib) bij kinderen van 4 tot en met 11 jaar met APDS Regulatory Filings	2026-02-02	Dutch
6-K Filing Regulatory Filings	2026-02-02	English
6-K Regulatory Filings	2026-01-08	English
Pharming Group reports preliminary 2025 revenues and announces Investor Day Earnings Release FY 2025	2026-01-08	Dutch
Pharming Group reports preliminary 2025 revenues and announces Investor Day Earnings Release FY 2025	2026-01-08	English

Filings by year

2026 38 filings
2025 60 filings
2024 60 filings
2023 64 filings
2022 56 filings
2021 48 filings
2020 44 filings
2019 17 filings
2018 18 filings
2017 22 filings
2016 25 filings
2015 21 filings
2014 19 filings
2013 26 filings
2012 59 filings
2011 34 filings
2010 52 filings
2009 40 filings
2008 29 filings
2007 44 filings
2006 23 filings
2005 6 filings